2. Others

Others

Others

Related Products

PDF 58.49 MB

There are a number of inhibitors, agonists, and antagonists which we cannot make precise classification because the research area is still unknown.

Others Related Products (73860):

Cat. No. Product Name CAS No. Purity Chemical Structure
  • HY-19043
    RS-93522 104060-12-0 98%
    RS-93522 (RS-93522-004) is a compound with calcium channel antagonist activity that is rapidly absorbed and has high bioavailability via nasal administration.
    RS-93522
  • HY-19047
    CD-349 88594-08-5 98%
    CD-349 is an active compound.
    CD-349
  • HY-19058
    NC-1300-B 104340-41-2 98%
    NC-1300-B is an active compound.
    NC-1300-B
  • HY-19074
    BMY-30047 83860-24-6 98%
    BMY-30047 is a retinoic acid derivative. BMY-30047 has topical retinoid activity. BMY-30047 has relative low local and systemic toxicity.
    BMY-30047
  • HY-19144
    ONO-3805 119347-91-0 98%
    ONO-3805 is an early lead compound of a non-steroidal 5α-reductase inhibitor, used to inhibit the conversion of testosterone to dihydrotestosterone, with potential effects in inhibiting benign prostatic hyperplasia.
    ONO-3805
  • HY-19156
    ZD-6888 138620-04-9 98%
    ZD-6888 is an active compound.
    ZD-6888
  • HY-19239
    FP-21399 170020-61-8 98%
    FP-21399 is an active compound.
    FP-21399
  • HY-19255
    FK-788 227951-89-5 98%
    FK-788 is a PGI(2) and IP agonist with a strong anti-aggregation effect, with an IC50 of 18 nM and a high binding affinity for the human recombinant IP receptor, with a Ki value of 20 nM.
    FK-788
  • HY-19267
    Ro-48-6791 172407-17-9 98%
    Ro-48-6791 is a compound that may have the activity of activating opioid receptors. Computational studies have found that it may bind to and activate opioid receptors, and may mediate or increase their related physiological effects and side effects.
    Ro-48-6791
  • HY-19375
    SB-235699 180869-32-3 98%
    SB-235699 is an active compound.
    SB-235699
  • HY-19405
    UK-224671 178309-91-6 98%
    UK-224671 is a potent and selective NK2 receptor antagonist. UK-224671 is affected by P-gp efflux and poor intrinsic membrane permeability, resulting in low oral bioavailability.
    UK-224671
  • HY-19407
    Nor-LY-510929 471854-50-9 98%
    Nor-LY-510929 is a compound whose development in the field of endocrinology and metabolism was stopped in 2005. Its specific active mechanism and application details are not described in detail based on the existing information.
    Nor-LY-510929
  • HY-19418
    KRP-101 311770-26-0 98%
    KRP-101 is a compound that regulates the expression of genes related to lipid metabolism. It is a PPARα agonist that can highly sensitively regulate the expression of genes such as apolipoprotein A-IV, which may be related to lowering serum triglycerides and increasing HDL.
    KRP-101
  • HY-19444
    DDB-S 213456-57-6 98%
    DDB-S does not alter the protein binding properties of ICG, but increases its clearance rate. DDB-S can increase liver blood flow. DDB-S can be used to observe changes in liver blood flow.
    DDB-S
  • HY-19500
    SC-75416 215122-74-0 98%
    SC-75416 is a selective cyclooxygenase-2 inhibitor. Its pharmacokinetic/pharmacodynamic (PK/PD) model was used for development and clinical trial simulation to design a study protocol to verify its analgesic effect in a post-oral surgery pain model. The simulation results showed that 360 mg of SC-75416 may provide better pain relief than 400 mg of ibuprofen. The actual clinical trial results confirmed this hypothesis, and 360 mg of SC-75416 was indeed superior to 400 mg of ibuprofen in pain relief. The PK/PD model of SC-75416 showed good predictive performance and successfully predicted its clinical effect. These research results show that SC-75416, as a new selective COX-2 inhibitor, has potential clinical application value in the management of post-oral surgery pain.
    SC-75416
  • HY-19521
    SRX251 512784-94-0 98%
    SRX251 is an active compound.
    SRX251
  • HY-19641
    AH13205 148436-63-9 98%
    AH13205 is a selective prostanoid EP2-receptor agonist. AH13205 causes concentration-related relaxations of Carbachol (HY-B1208)-contracted trachea. AH13205 causes dose-related protection against Histamine (HY-B1204)-induced increases in respiratory rate.
    AH13205
  • HY-19846
    VRX-03011 869493-26-5 98%
    VRX-03011 (PRX-03140 (potassium salt)) is a compound with the potential to enhance memory and regulate acetylcholine release. It is a 5-HT? agonist that can enhance memory, regulate hippocampal acetylcholine efflux, and regulate APP metabolism without gastrointestinal side effects.
    VRX-03011
  • HY-19905
    GW-597901 452339-68-3 98%
    GW-597901 is a compound with bronchodilator activity that has a stronger bronchodilator effect than salbutamol in a human lung reperfusion model, but with a slightly slower onset of action.
    GW-597901
  • HY-20003
    (-)-Corey lactone benzoate 39746-00-4 98.0%
    (-)-Corey lactone benzoate is a building block in the chemical synthesis of corey aldehyde.
    (-)-Corey lactone benzoate